Clinical Trial

Trial to Evaluate Efficacy and Safety of Subcutaneous Mosunetuzumab in Previously Untreated Low Tumor Burden Follicular Lymphoma .

Study acronym: SUNFLOW
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a multi-center, open-label, interventional clinical trial designed to evaluate the efficacy and safety of subcutaneous (SC) Mosunetuzumab as a first-line immunotherapy in patients with low tumor burden follicular lymphoma (LTB-FL), defined by the absence of GELF criteria.
Protocol Amendment History 5 changes
critical Recruitment opened 2026-08-12
critical Primary endpoint(s) modified 2026-08-12
notable Enrollment increased: 30 -> 40 participants 2026-08-12
notable Trial sites expanded: 0 -> 4 locations 2026-08-12
minor Completion pushed: 2029-03-01 -> 2030-03-01 2026-08-12
Trial Details
NCT Number NCT07191249
Lead Sponsor Tel-Aviv Sourasky Medical Center
Collaborators: Hoffmann-La Roche
Conditions Follicular Lymphoma
Enrollment 40 participants
Start Date 2026-01-05
Primary Completion 2028-04-01 (estimated)
Study Completion 2030-03-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-11